Create an Account
  1. Home
  2. Specialty
  3. Retina

Are You Ready for the Future? Treating GA With Complement Modulation-Based Therapies

Are You Ready for the Future Treating GA With Complement ModulationBased Therapies
Media formats available:
Details
Presenters

  • Overview

    Now that a treatment for geographic atrophy (GA) is entering the US market, retina specialists will need to be familiar with the safety and efficacy data of the pivotal trials evaluating this therapy. Drs. Kaiser, Kuppermann, and Loewenstein examine the data for the first US FDA-approved treatment for GA as well as other complement inhibitors in the pipeline. The faculty also discuss risk factors that drive this disease, imaging modalities that are best suited for GA evaluation, and the type of lesion patterns that place patients at high risk for progression.

    This program was recorded at the Congress on Controversies in Ophthalmology (COPHy). 

     

    This activity is supported by an unrestricted educational grant from Iveric Bio.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Summarize updates in the classification for dry age-related maculardegeneration, in particular the significance of incomplete retinalpigment epithelial and outer retinal atrophy (iRORA) and completeretinal pigment epithelial and outer retinal atrophy (cRORA)
    • Discuss anatomical retinal features that may serve as biomarkers of geographic atrophy (GA) progression
    • List lesion-specific factors that may predict treatment response
    • Explain the role of the complement pathway in GA development and progression
    • Evaluate clinical trial evidence for pipeline complement modulation-based therapies

    • Accreditation

      Provided by Evolve Medical Education 

      Accreditation Statement
      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
      The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu

       

    • Faculty and Disclosures

      Peter K. Kaiser, MD

      Peter K. Kaiser, MD

      Chaney Family Endowed Chair in Ophthalmology Research
      Professor of Ophthalmology
      Cleveland Clinic Lerner College of Medicine
      Cole Eye Institute
      Cleveland, OH


      Baruch D. Kuppermann, MD, PhD

      Baruch D. Kuppermann, MD, PhD

      Roger F. Steinert Professor and Chair
      Department of Ophthalmology, School of Medicine
      Director, Gavin Herbert Eye Institute
      Professor, Dept of Biomedical Engineering
      The Henry Samueli School of Engineering
      University of California, Irvine
      Irvine, CA


      Prof. Anat Loewenstein, MD, MHA

      Prof. Anat Loewenstein, MD, MHA

      Professor and Director, Division of Ophthalmology  
      Tel Aviv Medical Center
      VP Ambulatory Services
      Tel Aviv University
      President, Israeli Ophthalmological Society
      Tel Aviv, Israel


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Peter K. Kaiser, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX Therapeutics, Aviceda, Bayer, Bausch + Lomb, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Coherus, Complement Therapeutics, DelSiTech, Dompé, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Genentech/Roche, Glaukos, Innovent, iRenix, Iveric Bio, jCyte, Kanaph Therapeutics, Kanghong, Kera Therapeutics, Kodiak Sciences, Kriya Therapeutics, Nanoscope Therapeutics, Novartis, Ocugenix, Ocular Therapeutix, Oculis, Ocuphire Pharma, OcuTerra, Omeros, Oxurion, Palatin, Regeneron, Regenxbio, Resonance Medicine, RetinaAI Medical AG, Retinal Sciences, Roivant, Samsung Bioepis, SGN Nanopharma, Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa Pharma, and Unity Biotechnology.

      Baruch D. Kuppermann, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan and Genentech. Consultant: Aciveda, Allegro Ophthalmics, Allergan, Clearside Biomedical, EyeBio, Eyedaptic, Genentech, Glaukos, InflammX Therapeutics, Iveric Bio, jCyte, Novartis, Regeneron, ReVana Therapeutics, Ripple Therapeutics, and Theravance Biopharma. Grant/Research Support: Allegro Ophthalmics, Allergan, Apellis Pharmaceuticals, Genentech, Ionis, Iveric Bio, Novartis, Regeneron, and Regenxbio.

      Prof. Anat Loewenstein, MD, MHA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Annexon, Beyeonics, Biogen, Forsightlabs, Iqvia, Iveric Bio, Johnson & Johnson Vision, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, OcuTerra, OphtiMedRx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane.

      The Evolve staff, planners, and reviewer have no financial relationships or affiliations with ineligible companies.

       

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Iveric Bio.
      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

       

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free